Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol

Keyphrases

• Acute Radiation 33%
• Carcinoma 33%
• Cell Head 33%
• Chemoradiation 100%
• Chemotherapy 33%
• Cisplatin 66%
• Clinical Outcomes 33%
• Control Arm 33%
• Dose Escalation 66%
• EudraCT 33%
• Head-and-neck Cancer 33%
• Hypopharynx 33%
• LAHNSCC 100%
• Locally Advanced 33%
• Locoregional 100%
• Lymph Node 33%
• Modern Radiotherapy Technique 33%
• Neck Tumor 100%
• Oral Cavity 33%
• Oropharynx 33%
• Patient's Will 33%
• Platinum-based 33%
• Positron Emission Tomography-computed Tomography (PET-CT) 33%
• Primary Tumor 33%
• Prospective Randomized Trial 33%
• Radiation Dose Escalation 100%
• Radiation Protection 33%
• Radiation Toxicity 33%
• Radiochemotherapy 100%
• Randomized Phase III Trial 33%
• SIB-IMRT 33%
• Squamous Cell 33%
• Standard of Care 33%
• Total Dose 100%
• Trial Registration 33%
• Tumor Control 100%
• Tumor Hypoxia 100%
• Weekly Cisplatin 33%

Medicine and Dentistry

• Arm 66%
• Carcinoma 33%
• Chemoradiotherapy 100%
• Cisplatin 100%
• Head and Neck Cancer 33%
• Head and Neck Tumor 100%
• Hypopharynx 33%
• Intensity Modulated Radiation Therapy 66%
• Lymph Node 33%
• Neutron Capture Therapy 33%
• Oral Cavity 33%
• Oropharynx 33%
• Positron Emission Tomography-Computed Tomography 33%
• Primary Health Care 33%
• Primary Tumor 33%
• Radiation Dose Escalation 100%
• Radiation Protection 33%
• Radiation Therapy 33%
• Squamous Cell 33%
• Tumor 100%
• Tumor Hypoxia 100%